Sialic acid and oxidizability of lipid and proteins and antioxidant status in patients with coronary artery disease

Cell Biochemistry and Function

Volumn 25, Issue 6, 2007, Pages 655-664

  Serdar, Zehra ^a   Yeşilbursa, Dilek ^a   Dirican, Melahat ^a   Sarandöl, Emre ^a   Serdar, Akin ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Malondialdehyde; Paraoxonase; Protein carbonyls; Total sialic acid; Vitamin C; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ASCORBIC ACID; BIOLOGICAL MARKER; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SIALIC ACID; ANTIOXIDANT; LIPID; N ACETYLNEURAMINIC ACID;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; LIPID BLOOD LEVEL; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN OXIDATION; SPECTROMETRY; ANALYSIS OF VARIANCE; BLOOD; HOSPITALIZATION; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; RISK;

ANGINA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ASCORBIC ACID; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; LIPIDS; MALE; MALONDIALDEHYDE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; ODDS RATIO; OXIDATION-REDUCTION; SEVERITY OF ILLNESS INDEX; VITAMIN E;

EID: 38449096687     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1369     Document Type: Article

References (46)

1. Millar JS. The sialylation of plasma lipoproteins. Atherosclerosis 2001; 154: 1-13.
2. Lindberg G, Rastam L, Gullberg B, Eklund GA. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54,385 men and women during 20.5 years follow-up. Int J Epidemiol 1992; 21: 253-257.
3. Lindberg G, Eklund GA, Gullberg B, Rastam L. Serum sialic acid concentration and cardiovascular mortality. BMJ 1991; 302: 533-534.
4. Allain P, Olivier E, Le Bouil A, Benoit C, Geslin P, Tadei A. Increase of sialic acid concentration in the plasma of patients with coronary disease. Presse Med 1996; 25: 96-98.
5. Wakabayashi I, Sakamoto K, Yoshimoto S, Kakishita E. Serum sialic acid concentration and atherosclerotic risk factors. J Atheroscler Thromb 1994; 1: 113-117.
6. Watts GF, Crook MA, Haq S, Mandalia S. Serum sialic acid as an indicator of change in coronary artery disease. Metabolism 1995; 44: 147-148.
7. Salomone OA, Crook JR, Hossein-Nia M, Holt D, Kaski JC. Serum sialic acid concentration is not associated with the extent or severity of coronary artery disease in patients with stable angina pectoris. Am Heart J 1998; 136: 620-623.
8. Wu EB, Lumb P, Chambers JB, Crook MA. Plasma sialic acid and coronary artery atheromatous load in patients with stable chest pain. Atherosclerosis 1999; 145: 261-266.
9. Gökmen SS, Kiliçli G, Özçelik F, Ture M, Gülen S. Association between serum total and lipid-bound sialic acid concentration and the severity of coronary atherosclerosis. J Lab Clin Med 2002; 140: 110-118.
10. Lindbohm N, Gylling H, Miettinen TA. Sialic acid content of low density lipoprotein and its relation to lipid concentrations and metabolism of low density lipoprotein and cholesterol. J lipid Res 2000; 41: 1110-1117.
11. Melnichenko AA, Tertov VV, Ivanova OA, et al. Desialylation decreases the resistance of apo B-containing lipoproteins to aggregation and increases their atherogenic potential. Bull Exp Biol Med 2005; 140: 51-54.
12. Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS, Lele RD. Free radicals and antioxidants in human health: current status and future prospects. J Assoc Physicians India 2004; 52: 794-804.
13. Schwenke DC. Antioxidants and atherogenesis. J Nutr Biochem 1998; 9: 424-445.
14. Durrington PN, Mackness B, Mackness MI, Paraoxonase, atherosclerosis. Arterioscler Tromb Vasc Biol 2001; 21: 473-480.
15. Sies H, Stahl W. Vitamins E and C, β-carotene, and other carotenoids as antioxidants. Am J Clin Nutr 1995; 62: 1315-1322.
16. Dincer Y, Akcay T, Konukoglu D, Hatemi H. Erythrocyte susceptibility to lipid peroxidation in patients with coronary atherosclerosis. Acta Med Okayama 1999; 53: 259-264.
17. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162: 221-225.
18. Akkuş I, Saǧlam NI, Çaǧlayan O, Vural H, Kalak S, Saǧlam M., Investigation of erythrocyte membrane lipid peroxidation and antioxidant defense systems of patients with coronary artery disease (CAD) documented by angiography. Clin Chim Acta 1996; 244: 173-180.
19. Azarsiz E, Kayikcioǧlu M, Payzin S, Sözmen EY. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 2003; 91: 43-51.
20. Eguchi H, Ikeda Y, Ookawara T, et al. Modification of oligosaccharides by reactive oxygen species decreases sialyl Lewis x-mediated cell adhesion. Glycobiology 2005; 15: 1094-1101.
21. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease assessment in asymptomatic people. Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104: 1863-1867.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
23. Sydow G. A simplified quick method for determination of sialic acid in serum. Biomed Biochem Acta 1985; 44: 1721.
24. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991; 28: 504-508.
25. Zhang A, Vertommen J, Van Gaal L, De Leeuw I. A rapid and simple method for measuring the susceptibility of low-density-lipoprotein and very-low-density lipoprotein to copper-catalyzid oxidation. Clin Chim Acta 1994; 227: 159-173.
26. Mosca L, Rubenfire M, Tarshis T, Tsai A, Pearson T. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 1997; 80: 825-830.
27. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
28. Stocks J, Offerman EL, Modell CB, Dormandy TL. The susceptibility to autoxidation of human red cell lipids in health and disease. Br J Haematol 1972; 23: 713-724.
29. Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233: 357-363.
30. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
31. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-395.
32. Teissier E, Walters-Laporte E, Duhem C, Luc G, Fruchart JC, Duriez P. Rapid quantification of α-tocopherol in plasma and low- and high-density lipoproteins. Clin Chem 1996; 42: 430-435.
33. McCormick DB, Greene HL. Vitamins. In Tietz Textbook of Clinical Chemistry, series 2, Burtis CA, Ashwood ER (eds). W.B. Saunders Co: Philadelphia, 1994; 313-314.
34. Neeld JB, Pearson WN. Macro-and micromethods for determination of serum vitamin A using trifluoroacetic acid. J Nutr 1963; 79: 454-462.
35. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
36. Tertov VV, Kaplun VV, Sobenin IA, Orekhov AN. Low density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification. Atherosclerosis 1998; 138: 183-195.
37. Cerne D, Jurgens G, Ledinski G, Kager G, Greilberger J, Lukac-Bajalo J. Relationship between the sialic acid content of low density lipoprotein (LDL) and autoantibodies to oxidized LDL in the plasma of healthy subjects and patients with atherosclerosis. Clin Chem Lab Med 2002; 40: 15-20.
38. Tanaka K, Tokumaru S, Kojo S. Possible involvement of radical reactions in desialylation of LDL. FEBS Lett 1997; 413: 202-204.
39. Gökmen SS, Kiliçli G, Özçelik F, Gülen S. Serum total and lipid-bound sialic acid levels following acute myocardial infarction. Clin Chem Lab Med 2000; 38: 1249-1255.
40. Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, Orekhov AN. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 2001; 159: 103-115.
41. Rastam L, Lindberg G, Folsom AR, Burke GL, Nilsson-Ehle P, Lundblad A. Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. The ARIC Investigators. Atherosclerosis Risk in Communities Study. Int J Epidemiol 1996; 25: 953-958.
42. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest 1992; 67: 665-675.
43. Bridges AB, Scott NA, Pringle TH, McNeill GP, Belch JJ. Relationship between the extent of coronary artery disease and indicators of free radical activity. Clin Cardiol 1992; 15: 169-174.
44. Tamer L, Sucu N, Polat G, et al. Decreased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serum malondialdehyde in atherosclerotic patients. Arch Med Res 2002; 33: 257-260.
45. Hadengue AL, Del-Pino M, Simon A, Levenson J. Erythrocyte disaggregation shear stress, sialic acid, and cell aging in humans. Hypertension 1998; 32: 324-330.
46. Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase I activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349: 1605-1613.